EC approves Actelion’s Ledaga for treatment of cutaneous T-cell lymphoma
The European Commission (EC) has granted marketing authorization to Actelion Pharmaceuticals for its innovative Ledaga Chlormethine Gel 160 micrograms/g, designed for the treatment of cutaneous ... Read More